author-photo

Christine Theodore

Institut Gustave Roussy

271

Papers

8734

Citations

Citation Trend

Filter By

Papers (184) Sort By

Journal Conference Others

713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

2021
Show All
- Source
- Cite
- Save
Citations (0)
PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY

2020 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (15)
CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer

2020 Journal of Clinical Urology
Show All
- Source
- Cite
- Save
Citations (0)
The Impact of Cisplatin‐ or Non‐Cisplatin‐Containing Chemotherapy on Long‐Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (8)
LBA13CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)